Your browser is no longer supported. Please, upgrade your browser.
Settings
ACOR Acorda Therapeutics, Inc. daily Stock Chart
ACOR [NASD]
Acorda Therapeutics, Inc.
Index- P/E- EPS (ttm)-7.24 Insider Own1.85% Shs Outstand49.53M Perf Week9.50%
Market Cap108.47M Forward P/E- EPS next Y-1.44 Insider Trans0.00% Shs Float47.98M Perf Month-9.13%
Income-343.80M PEG- EPS next Q-0.54 Inst Own- Short Float29.55% Perf Quarter-19.78%
Sales211.10M P/S0.51 EPS this Y108.70% Inst Trans-0.17% Short Ratio7.72 Perf Half Y-80.32%
Book/sh5.92 P/B0.37 EPS next Y33.90% ROA-28.50% Target Price5.58 Perf Year-89.38%
Cash/sh5.11 P/C0.43 EPS next 5Y29.00% ROE-65.70% 52W Range1.58 - 21.13 Perf YTD-85.94%
Dividend- P/FCF- EPS past 5Y0.20% ROI3.90% 52W High-90.63% Beta1.22
Dividend %- Quick Ratio3.10 Sales past 5Y7.00% Gross Margin77.40% 52W Low25.32% ATR0.29
Employees474 Current Ratio3.40 Sales Q/Q-66.60% Oper. Margin- RSI (14)39.16 Volatility17.97% 13.82%
OptionableYes Debt/Eq1.25 EPS Q/Q- Profit Margin- Rel Volume0.79 Prev Close2.19
ShortableYes LT Debt/Eq1.25 EarningsNov 04 AMC Payout- Avg Volume1.84M Price1.98
Recom3.10 SMA20-11.36% SMA50-28.60% SMA200-75.68% Volume1,149,900 Change-9.59%
Aug-14-19Downgrade H.C. Wainwright Buy → Neutral $31 → $6
May-23-19Initiated Wedbush Neutral
Dec-11-18Downgrade Goldman Neutral → Sell
Aug-07-18Reiterated Stifel Hold $15 → $25
Feb-16-18Upgrade Piper Jaffray Neutral → Overweight
Jan-17-18Reiterated H.C. Wainwright Buy $34 → $31
Nov-28-17Resumed Piper Jaffray Neutral $22
Nov-16-17Downgrade Stifel Buy → Hold $26 → $15
Nov-16-17Downgrade Raymond James Mkt Perform → Underperform
Nov-09-17Initiated Oppenheimer Perform
Nov-08-17Initiated H.C. Wainwright Buy $35
Oct-06-17Resumed Goldman Sell $20
Jul-11-17Initiated Jefferies Hold
Apr-03-17Downgrade JP Morgan Overweight → Neutral
Feb-15-17Upgrade Goldman Sell → Neutral
Nov-30-16Upgrade JP Morgan Neutral → Overweight
Oct-04-16Resumed Leerink Partners Mkt Perform $25
Mar-30-16Initiated Goldman Sell
Sep-01-15Initiated Raymond James Mkt Perform
Jun-09-15Initiated Guggenheim Neutral
Nov-12-19 07:00AM  Acorda Therapeutics Announces Departure of President, International & General Counsel Business Wire -9.59%
Nov-08-19 10:21AM  Is Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) CEO Paid Enough Relative To Peers? Simply Wall St.
Nov-07-19 11:08AM  Zoetis (ZTS) Beats on Earnings in Q3, Reports In-Line Sales Zacks
11:05AM  Horizon Therapeutics' (HZNP) Q3 Earnings Beat Estimates Zacks
11:04AM  Esperion (ESPR) Reports Wider-Than-Expected Loss in Q3 Zacks
08:50AM  Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1% Zacks
Nov-06-19 04:40PM  Were Hedge Funds Right About Dumping Acorda Therapeutics Inc (ACOR)? Insider Monkey
04:28PM  Edited Transcript of ACOR earnings conference call or presentation 4-Nov-19 9:30pm GMT Thomson Reuters StreetEvents
10:56AM  Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View Zacks
10:34AM  Intercept (ICPT) Earnings and Sales Miss Estimates in Q3 Zacks
Nov-05-19 11:45AM  Acorda (ACOR) Q3 Earnings and Revenues Surpass Estimates Zacks +19.00%
11:09AM  Agenus (AGEN) Q3 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Nov-04-19 05:25PM  Acorda Therapeutics (ACOR) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:00PM  Acorda Provides Update for Third Quarter Ended September 30, 2019 Business Wire
11:18AM  AMAG Q3 Loss Wider Than Expected, Revenues Lag Estimates Zacks
Nov-01-19 02:49PM  Repligen (RGEN) Beats on Q3 Earnings, Lifts 2019 Guidance Zacks +21.21%
12:07PM  Agios' (AGIO) Q3 Loss Narrower Than Expected, Revenues Miss Zacks
Oct-31-19 12:40PM  Immunomedics (IMMU) Reports Wider-Than-Expected Loss in Q3 Zacks -9.84%
12:33PM  Vertex (VRTX) Q3 Earnings Beat, Revenues Lag Estimates Zacks
11:54AM  Medicines Company (MDCO) Incurs Wider-Than-Expected Q3 Loss Zacks
09:26AM  Insmed (INSM) in Focus: Stock Moves 7.1% Higher Zacks
Oct-28-19 10:32AM  Acorda Therapeutics (ACOR) Expected to Beat Earnings Estimates: Should You Buy? Zacks
Oct-25-19 07:12AM  The Daily Biotech Pulse: Melinta Crosses FDA Hurdle But Sees Liquidity Pushback, Positive Readout For Aclaris Wart Drug Benzinga
Oct-24-19 11:24AM  Acorda (ACOR) to Post Q3 Earnings: What's in the Cards? Zacks -26.06%
07:36AM  The Daily Biotech Pulse: Acorda To Trim Jobs, GlaxoSmithKline Gets FDA Nod, Edward Lifesciences Posts Q3 Beat-And-Raise Benzinga
Oct-23-19 04:00PM  Acorda Therapeutics Implements Corporate Restructuring, Provides Third Quarter 2019 Update Business Wire +11.78%
Oct-22-19 07:00AM  Acorda Launches New Tool for People with Parkinsons to Improve Communication About OFF Periods Business Wire
Oct-21-19 07:00AM  Acorda Third Quarter 2019 Update: Webcast/Conference Call Scheduled for November 4, 2019 Business Wire
Oct-07-19 10:00AM  UPDATE 1-U.S. Supreme Court rejects Acorda appeal in MS drug patent fight Reuters
Oct-03-19 09:00AM  Acorda (ACOR) Upgraded to Buy: Here's What You Should Know Zacks
Sep-26-19 08:40AM  Medicines Company (MDCO) Jumps: Stock Rises 5.5% Zacks
Sep-25-19 06:22PM  Protalix Completes Enrollment in Third Fabry Disease Study Zacks
06:18PM  Menlo (MNLO) Completes Enrollment in Phase II Pruritus Study Zacks
07:00AM  Acorda Therapeutics to Present at the 2019 Cantor Healthcare Conference Business Wire
Sep-18-19 10:33AM  Acceleron Discontinues Mid-Stage Muscular Dystrophy Study Zacks
08:42AM  Lexicon (LXRX) Catches Eye: Stock Jumps 7.3% Zacks
07:00AM  Acorda to Present Data at the International Congress of Parkinsons Disease and Movement Disorders Business Wire
Sep-16-19 10:29AM  Akari's Nomacopan Gets Orphan Drug Tag for Rare Skin Disease Zacks -7.51%
Sep-13-19 10:30AM  Celgene's (CELG) Leukemia Candidate Meets Endpoints in Study Zacks
08:42AM  Ligand (LGND) Surges: Stock Moves 6.3% Higher Zacks
Sep-12-19 08:35AM  Immunomedics (IMMU) Looks Good: Stock Adds 6.1% in Session Zacks
Sep-11-19 11:37AM  Ultragenyx to Submit sBLA for Label Expansion of Crysvita Zacks
Sep-10-19 09:01AM  Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks +26.98%
07:59AM  Horizon's (HZNP) Eye Disease Drug Gets FDA's Priority Review Zacks
Sep-09-19 03:51PM  Did Changing Sentiment Drive Acorda Therapeutics's (NASDAQ:ACOR) Share Price Down A Painful 91%? Simply Wall St. +12.50%
Sep-03-19 11:00AM  Acorda (ACOR) Down More Than 60% in 3 Months: Here's Why Zacks -8.98%
Aug-31-19 09:32AM  Why Is Acorda (ACOR) Down 46.8% Since Last Earnings Report? Zacks
Aug-23-19 09:15AM  Alexion Pharmaceuticals (ALXN) Jumps: Stock Rises 7.5% Zacks
07:38AM  Retrophin Down on Neurological Disorder Drug Study Failure Zacks
Aug-21-19 06:03PM  Synlogic Discontinues Development of SYNB1020, Stock Down Zacks
08:42AM  Moderna (MRNA) Jumps: Stock Rises 5.6% Zacks
Aug-20-19 08:34AM  Vanda Receives CRL From FDA for sNDA of Jet Lag Treatment Zacks +9.90%
07:44AM  Acorda Therapeutics Enters Oversold Territory Zacks
Aug-14-19 09:10AM  Kadmon (KDMN) Completes Enrollment in KD025 Study for cGVHD Zacks -12.45%
Aug-13-19 09:50AM  Regeneron Ebola Treatment Shows Promise, Study Stopped Early Zacks
Aug-12-19 08:37AM  Epizyme (EPZM) Q2 Loss In Line, Revenues Beat Estimates Zacks
Aug-09-19 11:09AM  Agenus (AGEN) Q2 Earnings Miss Estimates, Revenues Beat Zacks
Aug-08-19 10:45AM  Immunomedics (IMMU) Posts Wider-Than-Expected Loss in Q2 Zacks
10:15AM  Horizon Therapeutics' (HZNP) Q2 Earnings Beat Estimates Zacks
09:26AM  Catalyst's (CPRX) Q2 Earnings and Revenues Beat Estimates Zacks
Aug-07-19 05:40PM  Edited Transcript of ACOR earnings conference call or presentation 1-Aug-19 8:30pm GMT Thomson Reuters StreetEvents
Aug-02-19 11:54AM  Blueprint Medicines (BPMC) Q2 Loss Widens, Sales Top Mark Zacks -48.93%
10:53AM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
10:52AM  Emergent (EBS) Earnings Miss in Q2, Revenues Beat Estimates Zacks
10:48AM  Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss Zacks
10:43AM  IVERIC bio's (ISEE) Q2 Loss Narrows, Gene Therapy in Focus Zacks
08:24AM  Acorda Therapeutics (ACOR) Q2 2019 Earnings Call Transcript Motley Fool
Aug-01-19 06:45PM  Acorda Therapeutics (ACOR) Reports Q2 Loss, Tops Revenue Estimates Zacks -12.41%
04:00PM  Acorda Provides Update for Second Quarter Ended June 30, 2019 Business Wire
12:02PM  Agios' (AGIO) Loss Widens in Q2, Tibsovo Drives Sales Zacks
12:00PM  Vertex (VRTX) Beats on Q2 Earnings, Ups CF Product Sales View Zacks
09:54AM  Amgen (AMGN) Catches Eye: Stock Jumps 5.7% Zacks
Jul-31-19 11:32AM  Celgene (CELG) Beats on Q2 Earnings, Raises Revenue Guidance Zacks
Jul-26-19 10:38AM  Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2 Zacks
08:30AM  Acorda Receives Positive CHMP Opinion for INBRIJA (levodopa inhalation powder) Business Wire
Jul-25-19 11:25AM  Medicines Company (MDCO) Q2 Earnings Top, Inclisiran in View Zacks
11:10AM  Acorda (ACOR) to Post Q2 Earnings: What's in the Cards? Zacks
10:33AM  Analysts Estimate Acorda Therapeutics (ACOR) to Report a Decline in Earnings: What to Look Out for Zacks
Jul-24-19 05:50PM  Acorda Therapeutics (ACOR) Outpaces Stock Market Gains: What You Should Know Zacks
01:54PM  Alexion (ALXN) Q2 Earnings Beat Estimates, Guidance Raised Zacks
Jul-19-19 09:41AM  Horizon's NDA for Procysbi New Dosage Form Accepted by FDA Zacks
Jul-18-19 07:00AM  Acorda Second Quarter 2019 Update:  Webcast/Conference Call Scheduled for August 1, 2019 Business Wire
Jul-16-19 01:15PM  Exelixis Adds & Expands Cohorts in Cabometyx-Tecentriq Study Zacks
Jul-11-19 11:14AM  FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug Zacks
09:05AM  Horizon Therapeutics Files BLA to FDA for Eye Disease Drug Zacks
Jul-10-19 09:20AM  Is Acorda Therapeutics, Inc.'s (NASDAQ:ACOR) Balance Sheet A Threat To Its Future? Simply Wall St.
Jul-08-19 06:02PM  ObsEva Ends Recruitment in Second Uterine Fibroids Study Zacks
Jul-05-19 12:04PM  Catalyst Pharma Focuses on Firdapse Launch & Label Expansion Zacks
Jul-03-19 09:00AM  All You Need to Know About Acorda (ACOR) Rating Upgrade to Buy Zacks
Jun-28-19 09:56AM  Amgen's Osteoporosis Drug Evenity Gets Adverse CHMP View Zacks
Jun-27-19 10:18AM  Inovio Up on Enrollment Closure in Cervical Dysplasia Study Zacks +6.78%
Jun-26-19 06:17PM  Pacira Gets EMA Acceptance for Pain Management Drug Exparel Zacks
08:42AM  Revance Therapeutics (RVNC) Jumps: Stock Rises 5.2% Zacks
06:11AM  Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin Zacks
06:07AM  Conatus' Emricasan Lags Primary Goal in Liver Function Study Zacks
Jun-25-19 08:00AM  Alnylam Presents New Data for RNAi Therapeutic Onpattro Zacks
Jun-24-19 05:53PM  Epizyme Announces Positive Interim Data on Lead Candidate Zacks
05:45PM  AMAG's Vyleesi Gets FDA NOD for Women with Low Sexual Desire Zacks
11:04AM  BioMarin Gets $15M From Pfizer on Talzenna's European Nod Zacks
10:05AM  Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children Zacks
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) for primary sclerosing cholangitis. Further, it develops rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sabella Lauren MChief Commercial OfficerFeb 22Sale13.1876110,0285,092Feb 25 04:19 PM
LAWRENCE DAVIDChief, Bus. Ops & PAOFeb 22Sale13.1876110,0285,092Feb 25 04:17 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 30Sale16.017,000112,0394,750,219Feb 01 04:28 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 25Sale16.002,40138,4164,757,219Jan 28 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 24Sale16.038,600137,8514,759,620Jan 28 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 23Sale16.0145,898734,9424,768,220Jan 24 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 22Sale16.0251,945831,9724,814,118Jan 24 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 18Sale16.2439,358639,3274,866,063Jan 22 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 17Sale16.86100,0001,685,5504,905,421Jan 22 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 16Sale16.9491,6501,552,4145,005,421Jan 17 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 15Sale16.601,70028,2235,097,071Jan 17 04:06 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 11Sale17.4040,392702,7885,098,771Jan 15 04:32 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 10Sale17.2987,4911,512,7285,139,163Jan 11 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 09Sale17.0575,0001,278,7055,226,654Jan 11 04:18 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 08Sale16.2459,174960,9275,301,654Jan 09 04:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 07Sale16.5675,0001,241,7385,360,828Jan 09 04:22 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 04Sale16.6131,591524,7145,435,828Jan 07 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerJan 03Sale15.7423,616371,6455,467,419Jan 07 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 28Sale14.9952,891792,7515,491,035Jan 02 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 27Sale14.6650,000732,7605,543,926Dec 28 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 26Sale14.6650,000732,8205,593,926Dec 28 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 21Sale13.2440,506536,0975,643,926Dec 26 04:14 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 20Sale14.0340,000561,3685,684,432Dec 21 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 19Sale15.935,00079,6645,724,432Dec 21 04:11 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 18Sale16.9480,0001,354,9415,729,432Dec 19 04:10 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 17Sale16.4941,853690,1025,809,432Dec 19 04:10 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 14Sale16.1528,796464,9785,851,285Dec 17 05:48 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 13Sale16.2733,061537,7605,880,081Dec 17 05:48 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 12Sale16.30100,0001,629,7905,913,142Dec 13 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 11Sale16.30200,0003,259,5006,013,142Dec 13 04:09 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 10Sale19.0735,000667,5316,213,142Dec 11 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 07Sale18.7725,210473,0716,248,142Dec 11 04:08 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 06Sale18.4340,711750,3406,273,352Dec 07 04:45 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 04Sale20.603,09063,6596,314,063Dec 07 04:45 PM
Wasman JanePresident, Intl and GCDec 03Sale20.523,06762,947105,287Dec 06 08:42 AM
Sabella Lauren MChief Commercial OfficerDec 03Sale20.565,191106,7371,568Dec 06 08:31 AM
LAWRENCE DAVIDChief, Bus. Ops & PAODec 03Sale20.552,49351,2323,653Dec 06 08:22 AM
Hindman Andrew A.Chief Business OfficerDec 03Sale20.5675315,4785,171Dec 06 08:05 AM
COHEN RONPresident and CEODec 03Sale20.603,62074,554487,554Dec 06 08:00 AM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerDec 03Sale20.70100,0002,069,5006,317,153Dec 03 05:03 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerNov 30Sale20.4875,0001,536,0156,417,153Dec 03 05:03 PM
SCOPIA CAPITAL MANAGEMENT LP10% OwnerNov 29Sale20.2050,0001,009,8606,492,153Dec 03 05:03 PM
Randall LorinDirectorNov 26Sale19.981,90438,0340Nov 28 08:02 AM